Tone mix
Week by week 50 weeks
Share of Ultragenyx Pharmaceutical Inc.'s 240 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Aug 11, 2025 · tone -100Q3 EPS Estimate for Ultragenyx Pharmaceutical Cut by Analyst-91
- Week of Aug 17, 2026 · tone +100Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up After Analyst Upgrade+91
- Week of Apr 27, 2026 · tone +100Ultragenyx Pharmaceutical (RARE) Garnering Bullish Sentiment With Forthcoming GTX-102 Phase 3 Angelman Trial+90
- Week of Jun 8, 2026 · tone +100Institutional Confidence in GTX-102 Fuels Optimism for Ultragenyx Pharmaceutical (RARE)+83
- Week of Apr 13, 2026 · tone +83Rep. Gilbert Ray Cisneros, Jr. Buys Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares+78
- Week of Sep 29, 2025 · tone +99Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline+73
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Ultragenyx Pharmaceutical Inc. in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 4 | -6 |
| Last 30 sessions | 11 | +13 |
| Last 90 sessions | 50 | +3 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Friday, November 6, 2026
2 headlines, average tone -11: 1 positive, 0 neutral and 1 negative. Showing all 2.
- www.themarketsdaily.com · 1 outletBarclays Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock PriceNegative
- www.finanznachrichten.de · 1 outletUltragenyx Pharmaceutical Inc.: Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory AgenPositive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Barclays Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price | www.themarketsdaily.com | 1 | Negative |
| Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agen | www.finanznachrichten.de | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, November 5, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.fool.com · 1 outletUltragenyx (RARE) Q3 2026 Earnings Call TranscriptNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Ultragenyx (RARE) Q3 2026 Earnings Call Transcript | www.fool.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, November 4, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletWhat Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings CallNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Average Target Price of $33.65Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Average Target Price of $33.65 | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 15, 2026
2 headlines, average tone +32: 1 positive, 1 neutral and 0 negative. Showing all 2.
- www.tickerreport.com · 2 outletsUltragenyx (NASDAQ: RARE) agrees to sell PRV for $203 million in cashNeutral
- www.themarketsdaily.com · 1 outletRep. Gilbert Ray Cisneros, Jr. Buys Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Positive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Ultragenyx (NASDAQ: RARE) agrees to sell PRV for $203 million in cash | www.tickerreport.com | 2 | Neutral |
| Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Ultragenyx Pharmaceutical Inc., not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.